This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–11.
Morens DM, Taubenberger JK, Fauci AS. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host Microbe. 2023;31:146–57.
Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063.
Poovorawan Y, Chongsrisawat V, Theamboonlers A, Crasta PD, Messier M, Hardt K. Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand. Hum Vaccin Immunother. 2013;9:1679–84.
Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390:2143–59.
Dai YC, Lin YC, Ching LL, Tsai JJ, Ishikawa K, Tsai WY, et al. Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals. Microbiol Spectr. 2023;11:e0408122.
Li L, Liao H, Meng Y, Li W, Han P, Liu K, et al. Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1. Cell. 2022;185:2952–60.e10.
Meier A, Mehrle S, Weiss TS, Mier W, Urban S. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology. 2013;58:31–42.
Hashiguchi T, Kajikawa M, Maita N, Takeda M, Kuroki K, Sasaki K, et al. Crystal structure of measles virus hemagglutinin provides insight into effective vaccines. Proc Natl Acad Sci USA. 2007;104:19535–40.
McDermott BM Jr., Rux AH, Eisenberg RJ, Cohen GH, Racaniello VR. Two distinct binding affinities of poliovirus for its cellular receptor. J Biol Chem. 2000;275:23089–96.
Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N. Engl J Med. 2022;386:1288–90.
Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, et al. Measles antibody: reevaluation of protective titers. J Infect Dis. 1990;162:1036–42.
Jang B, Kim HW, Kim HS, Park JY, Seo H, Kim YK. Measles Virus Neutralizing Antibody Response and Durability Two Years after One or Two Doses of Measles-Mumps-Rubella Vaccine among Young Seronegative Healthcare Workers. Vaccines. 2022;10:1812.
Gans HA, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, Beeler J, et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis. 2004;190:83–90.
Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccin Immunol. 2010;17:1055–65.
Tang R, Chu K, Hu Y, Chen L, Zhang M, Liu S, et al. Effect of maternal antibody on the infant immune response to inactivated poliovirus vaccines made from Sabin strains. Hum Vaccin Immunother. 2019;15:1160–6.
Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg. 1972;70:767–77.
Jacobson RM, Grill DE, Oberg AL, Tosh PK, Ovsyannikova IG, Poland GA. Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers. Hum Vaccin Immunother. 2015;11:961–9.
Meng B, Abdullahi A, Ferreira I, Goonawardane N, Saito A, Kimura I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706–14.
Liu Y, Qu HQ, Qu J, Tian L, Hakonarson H. Expression Pattern of the SARS-CoV-2 Entry Genes ACE2 and TMPRSS2 in the Respiratory Tract. Viruses. 2020;12:1174.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (82388201 to JH), the National Key R&D Program of China (2020YFA0803500 to JH), the CAMS Innovation Fund for Medical Sciences (CIFMS) (2019-I2M-5-062 to JH), the Fujian Province Central to Local Science and Technology Development Special Program (2022L3079 to JH), and the Fu-Xia-Quan Zi-Chuang District Cooperation Program (3502ZCQXT2022003 to JH). The funders had no role in the decision to publish or the preparation of the manuscript. We thank Lu Zhou (Xiamen University) for proofreading and editing the manuscript.
Author information
Authors and Affiliations
Contributions
YL, DL and JH contributed to the writing of the manuscript and approved the submitted version.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Liu, Y., Li, D. & Han, J. COVID-19 vaccines and beyond. Cell Mol Immunol 21, 207–209 (2024). https://doi.org/10.1038/s41423-024-01132-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41423-024-01132-2